2-(3-氨基苯基)乙醇 | 52273-77-5

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3-氨基苯基)乙醇
• 中文别名: 3-氨基苯乙醇
• 英文名称: 2-(3-aminophenyl)ethan-1-ol
• 英文别名: 2-(3-aminophenyl)ethanol；3-(2-hydroxy ethyl)-phenyl amine
• CAS: 52273-77-5
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: FNUKLSVGSFFSLI-UHFFFAOYSA-N

物化性质

• 熔点：
  51-53 ºC
• 沸点：
  293 ºC
• 密度：
  1.124
• 闪点：
  131 ºC
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  应储存在室温、密封、干燥、避光的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-(3-Aminophenyl)ethanol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-(3-Aminophenyl)ethanol
CAS number: 52273-77-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H11NO
Molecular weight: 137.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(3-氨基苯基)乙醇 在 iron(III) chloride 、 N-碘代丁二酰亚胺 、 copper(l) iodide 、 caesium carbonate 、 1-丁基-3-甲基咪唑二(三氟甲基磺酰)酰亚胺 、 N,N'-二甲基乙二胺 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 52.0h， 生成 N-(2,3-dihydrobenzofuran-5-yl)acetamide
  参考文献：
  名称：

  铁和铜催化的芳基C–N和C–O键的形成合成功能化的吲哚和二氢苯并呋喃

  摘要：

  描述了一种简单有效的一锅两步分子内芳基C–N和C–O键形成过程，该过程可利用铁和铜催化制备各种苯并稠合的杂环骨架。对活化的芳基环进行高度区域选择性，三氟甲磺酸铁（III）催化的碘化，然后进行铜（I）催化的分子内N-或O-芳基化步骤，生成二氢吲哚，二氢苯并呋喃和六元类似物。该方法的一般适用性和官能团耐受性由新木脂素天然产物（+）-奥布他呋喃的全合成例示。还进行了使用Fukui函数的DFT计算，从而为高度区域选择性的芳烃碘化过程提供了分子轨道原理。

  DOI：

  10.1021/acs.joc.8b02888
• 作为产物：
  描述：

  3-硝基苯乙酸 在 dimethyl sulfide borane 、 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 2-(3-氨基苯基)乙醇
  参考文献：
  名称：

  [EN] QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS
  [FR] DÉRIVÉS DE QUINOLONE UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES

  摘要：

  公式(I)的化合物是成纤维细胞生长因子抑制剂（FGFR），因此可用于治疗可通过抑制FGFR治疗的疾病。还披露了包含此类化合物的药物组合物以及制备此类化合物的过程。

  公开号：

  WO2016191172A1

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• 2-AMINOQUINOLINES
  申请人：Kolczewski Sabine

  公开号：US20090227583A1

  公开（公告）日：2009-09-10

  The present invention relates to compounds of formula (I) wherein A, R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, pharmaceutical compositions containing them, and methods for their manufacture. These compounds are 5-HT 5A receptor antagonistsand are useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

  本发明涉及式(I)的化合物， 其中A，R1，R2，R3，R4和R5如本文所述，含有它们的药物组合物，以及其制备方法。这些化合物是5-HT5A受体拮抗剂，可用于预防和/或治疗抑郁症、焦虑障碍、精神分裂症、恐慌障碍、广场恐惧症、社交恐惧症、强迫症、创伤后应激障碍、疼痛、记忆障碍、痴呆症、进食行为障碍、性功能障碍、睡眠障碍、药物滥用、帕金森病等运动障碍、精神障碍或胃肠道障碍的治疗。
• Iodinated Choline Transport-Targeted Tracers
  作者：Pavel Švec、Zbyněk Nový、Jan Kučka、Miloš Petřík、Ondřej Sedláček、Martin Kuchař、Barbora Lišková、Martina Medvedíková、Kristýna Kolouchová、Ondřej Groborz、Lenka Loukotová、Rafał Ł. Konefał、Marián Hajdúch、Martin Hrubý

  DOI：10.1021/acs.jmedchem.0c01710

  日期：2020.12.24

  theranostics for diseases accompanied by pathological function of proteins involved in choline transport. Unlike choline analogues labeled with 11C or 18F that are currently used in the clinic, the iodinated compounds described herein are applicable in positron emission tomography, single-photon emission computed tomography, and potentially in therapy, depending on the iodine isotope selection. Moreover

  我们提出了一系列新颖的放射性碘示踪剂和潜在的疾病治疗学，伴随着胆碱转运蛋白的病理功能。与临床上当前使用的标有11 C或18 F的胆碱类似物不同，本文所述的碘化化合物可根据碘同位素选择，应用于正电子发射断层扫描，单光子发射计算机断层扫描以及潜在地用于治疗。而且，碘同位素的有利半衰期导致通过同位素交换反应的具有挑战性的合成要少得多。所描述的化合物中有六个是纳摩尔配体，最佳化合物的亲和力比胆碱高100倍。125的生物分布数据用I标记的人类前列腺癌（PC-3）小鼠配体显示了两种化合物，其生物分布特征优于[ 18 F]氟胆碱。
• [EN] QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS<br/>[FR] DERIVES DE QUINOLINE ET DE QUINAZOLINE PRESENTANT UNE AFFINITE VIS-A-VIS DES RECEPTEURS DU TYPE 5HT1
  申请人：GLAXO GROUP LTD

  公开号：WO2005014552A1

  公开（公告）日：2005-02-17

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

  提供了式(I)的化合物及其药用盐：其中R1、m、X、R2、n、W、p、Y、Z、R3、R4、R5和q的含义如描述中所定义。还公开了制备方法以及在治疗中的用途，特别是用于抑郁症或焦虑等中枢神经系统疾病。
• [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2019148005A1

  公开（公告）日：2019-08-01

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.

  揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统，治疗适合免疫系统调节的疾病，并用于体内、体外或体外细胞的治疗。